CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development expenses	$ 3,314	$ 4,129	$ 10,837	$ 12,571
General and administrative	2,494	5,012	12,344	21,876
Settlement expense			250
Total operating expenses	5,808	9,141	23,431	34,447
Loss from operations	(5,808)	(9,141)	(23,431)	(34,447)
Other (income) expenses:
Interest income	(119)	(95)	(420)	(119)
Interest expense	40		40	3
Change in fair value of convertible note payable	359		2,794
Change in fair value of warrant liabilities	(26)	37	(27)	(236)
Change in fair value of earnout cash liability				(4,582)
Total other (income) expenses	254	(58)	2,387	(4,934)
Net loss	(6,062)	(9,083)	(25,818)	(29,513)
Change in fair value of convertible note attributed to credit risk			22
Other comprehensive loss			22
Comprehensive loss	$ (6,062)	$ (9,083)	$ (25,840)	$ (29,513)
Net loss per share:
Basic	$ (0.07)	$ (0.14)	$ (0.35)	$ (0.45)
Diluted	$ (0.07)	$ (0.14)	$ (0.35)	$ (0.45)
Weighted average common shares outstanding:
Basic	81,946,957	66,449,593	74,114,180	65,532,409
Diluted	81,946,957	66,449,593	74,114,180	65,532,409